Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

• Published in: Breast cancer research : BCR Vol. 12; no. 4; p. R47
• Main Authors: Bartlett, John M S, Thomas, Jeremy, Ross, Douglas T, Seitz, Robert S, Ring, Brian Z, Beck, Rodney A, Pedersen, Hans Christian, Munro, Alison, Kunkler, Ian H, Campbell, Fiona M, Jack, Wilma, Kerr, Gillian R, Johnstone, Laura, Cameron, David A, Chetty, Udi
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 01.01.2010; National Library of Medicine - MEDLINE Abstracts; BioMed Central
• Subjects: Antineoplastic Agents, Hormonal - therapeutic use; Biomarkers, Tumor - metabolism; Breast cancer; Breast Neoplasms - diagnosis; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Cancer patients; Cancer research; Carcinoembryonic Antigen - metabolism; Care and treatment; Cell Cycle Proteins - metabolism; Chemotherapy; Chemotherapy, Adjuvant; Diagnostic Tests, Routine - methods; Disease-Free Survival; Estrogens; Female; GPI-Linked Proteins - metabolism; Health aspects; Humans; Immunohistochemistry; Intracellular Signaling Peptides and Proteins - metabolism; Large Neutral Amino Acid-Transporter 1 - metabolism; Lumpectomy; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Postmenopausal women; Prognosis; Receptors, Estrogen - metabolism; Recurrence (Disease); Reproducibility of Results; Risk Assessment - methods; Risk Factors; Sensitivity and Specificity; Tamoxifen; Tamoxifen - therapeutic use; Tumor proteins; Tumor Suppressor Protein p53 - metabolism

Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectiv...